Trial Profile

Anakinra in severe juvenile idiopathic arthritis of systemic onset (ANAJIS)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anakinra (Primary) ; Corticosteroid; Pneumococcal vaccine; Prednisolone; Prednisone
Indications Juvenile rheumatoid arthritis
Focus Therapeutic Use
Acronyms ANAJIS

Most Recent Events

16 Nov 2020 Results (n=286) of meta-analysis of 5 studies assessing relative efficacy and safety of canakinumab, anakinra, tocilizumab, and rilonacept in patients with active sJIA, published in the International Journal of Clinical Pharmacology and Therapeutics.
19 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
29 Oct 2008 Results were reported at the American College of Rheumatology and the Association of Rheumatology Health Professionals meeting in 2008.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com